SOLVE FSHD Announces $3 Million Investment in Armatus Bio to Advance Gene Therapy Program for FSHD

SOLVE FSHD announced a $3 million investment in Armatus Bio. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy designed to silence the expression of DUX4, the toxic protein responsible for muscle degeneration in individuals with facioscapulohumeral muscular dystrophy (FSHD).